87649-67-0

Usage

Uses

Used in Organic Synthesis:
(1S,3S,4E)-4-[(2E)-2-[(1R,3aR,7aS)-1-[(E,2S)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-6-methylidene-cyclohexane-1,3-diol is used as a building block in organic synthesis for the creation of various complex organic molecules. Its unique structure and potential chemical reactivity make it a valuable component in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Medicinal Chemistry:
(1S,3S,4E)-4-[(2E)-2-[(1R,3aR,7aS)-1-[(E,2S)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-6-methylidene-cyclohexane-1,3-diol is used as a key intermediate in the development of new pharmaceuticals. Its unique structure and potential reactivity can be exploited to design and synthesize novel drug candidates with improved therapeutic properties. (1S,3S,4E)-4-[(2E)-2-[(1R,3aR,7aS)-1-[(E,2S)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-6-methylidene-cyclohexane-1,3-diol's chiral centers also provide opportunities for the exploration of stereoselective synthesis and the development of enantiomerically pure drugs with enhanced efficacy and reduced side effects.

Upstream product

• 112670-78-7 (1S,5R)-5-(tert-Butyl-dimethyl-silanyloxy)-2-methylene-3-[2-[(R)-7a-methyl-1-((E)-(1R,4R)-1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-(4E)-ylidene]-eth-(Z)-ylidene]-cyclohexanol 
• 115540-28-8 1(S),3(R)-bis(tert-butyldimethylsilyloxy)-9,10-secoergosta-5(E),7(E),10⁽¹⁹⁾,22(E)-tetraene 
• 112670-78-7 1(S),3(R)-3-(tert-butyldimethylsilyl)-9,10-secoergosta-5(E),7(E),10⁽¹⁹⁾,22(E)-tetraene-1-ol 
• 125091-76-1 2,3-dimethylbutylmagnesium bromide 
• 125091-79-4 (S)-2,3-dimethylbutyl p-tolyl sulphone 
• 125091-77-2 (2S)-2,3-dimethylbutyl (S)-p-tolyl sulphoxide 
• 125091-81-8 (2S,5S)-2-{(1R,3aS,7aR)-4-[2-[(3S,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-2-methylene-cyclohex-(Z)-ylidene]-eth-(E)-ylidene]-7a-methyl-octahydro-inden-1-yl}-5,6-dimethyl-4-(toluene-4-sulfonyl)-heptan-3-ol 
• 112924-91-1 (5Z,7E)-(1S,3R,20S)-1,3-bis<(tert-butyldimethylsilyl)oxy>-9,10-seco-22,23-dinor-5,7,10(19)-cholatrien-24-al 
• 125136-23-4 (1R,3aS,7aR)-4-[2-[(3S,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-2-methylene-cyclohex-(Z)-ylidene]-eth-(E)-ylidene]-7a-methyl-1-((E)-(1R,4S)-1,4,5-trimethyl-hex-2-enyl)-octahydro-indene 
• 72244-09-8 C₂₉H₄₆O₂ 
• 72205-00-6 C₂₉H₄₆O 
• 72204-99-0 vitamin D₂ p-toluenesulfonate 
• 50-14-6 Calciferol 
• 108-31-6 maleic anhydride 

Downstream Products

• 111594-59-3 tert-Butyl-dimethyl-{(S)-5-[2-[(1R,3aS,7aR)-7a-methyl-1-((E)-(1R,4R)-1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-(4E)-ylidene]-eth-(E)-ylidene]-4-pentyl-cyclohex-3-enyloxy}-silane 

Relevant academic research and scientific papers

Degree-of-freedom alcohol and preparation method thereof

The invention provides alcidol and a preparation method thereof, and the preparation method comprises the following steps: D. 2 The initial material is subjected to a sulfonylation reaction in sequence. The methoxy - is reacted with a bridging

Preparation method of 1alpha-hydroxyvitamin D2

The invention provides a preparation method of 1alpha-hydroxyvitamin D2. The method comprises the following steps: 1, carrying out a halogenation reaction on vitamin D2 by using a halogenation reagent in an organic solvent; 2, carrying out a hydrolysis re

Development of an improved process for doxercalciferol via a continuous photochemical reaction

Doxercalciferol (1α-hydroxyvitamin D2) is a commercially approved vitamin D derivative used to treat chronic kidney disease (CKD) patients whose kidneys cannot metabolically introduce a hydroxyl group at C1. A new process for the production of doxercalcif

CONTINUOUS PHOTOLYTIC PROCESS FOR THE PREPARATION OF VITAMIN D RELATED SUBSTANCES

The present application provides a novel method for generation of a vitamin D2 compound using a continuous flow photoisomerization reactor. A compound represented by formula I: [structure] as further defined herein, is mixed with a solvent and a sensitize

STABILIZED DOXERCALCIFEROL AND PROCESS FOR MANUFACTURING THE SAME

1 a-hydroxy vitamin D2 (doxercalciferol) of exceptionally high purity and stability is prepared by a process involving chromatographically purifying 1 α-hydroxyvitamin D2 monoacetate, chemically removing the acetate protectant group

Stabilized hydroxyvitamin D

The invention provides a stabilized 1α-hydroxyvitamin D (“SHVD”) which is particularly well suited for pharmaceutical formulations.

VITAMIN D DERIVATIVES AND PROCESS FOR PRODUCING THE SAME

A process for producing hydroxyvitamin D derivatives, characterized by converting a hydrogen atom or atoms at the 2-position, 24-position, 25-position and/or 26-position of a vitamin D into a hydroxyl group or groups in a solution containing a microorganism that belongs to the genus Nocardia, Streptomyces,Sphingomonas or Amycolata which has an ability to hydroxylate vitamin Ds or an enzyme produced by that microorganism, and optionally under the coexistence of a cyclodextrin; and novel vitamin D3 derivatives obtained by that process.

Method for preparing intermediates for the synthesis of steroid side chains in optically active form

This invention provides a novel method for the preparation of optically active arylalykylsulfone derivatives, having a chiral center in the alkyl moiety in either the (R)- or the (S)-configuration. These optically active sulfones find use in the stereospe

A Convenient Synthesis of (24S)-1-α-Hydroxyvitamin D2

A new method was developed for the synthesis of (2R)- and (2S)-2,3-dimethylbutyl p-tolyl sulphone from a chiral sulphinate ester, and applied to the synthesis of (24S)-1α-hydroxyvitamin D2; this new 24-epimer of vitamin D2 has a distinct biological activi